Clinical trials: Papillary Renal Cell Carcinoma, active
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other…
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma
- Trial name
- NCT03866382
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 581 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- National Cancer Institute (NCI)
Papillary Renal Cell Carcinoma
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell…
- Trial name
- SAMETA (NCT05043090)
- Testing
- savolitinib, durvalumab, sunitinib
- Where
- 139 sites in United States, Argentina and 23 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed.
- Trial name
- NCT05665361
- Testing
- Sasanlimab, Palbocicilib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started…
- Trial name
- NCT05411081
- Testing
- Atezolizumab, Biospecimen Collection, Bone Scan
- Where
- 198 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started…
- Conditions
- Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma
- Trial name
- NCT04981509
- Testing
- Atezolizumab, Bevacizumab, Biopsy Procedure
- Where
- 13 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone.
- Conditions
- Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma
- Trial name
- NCT04071223
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 47 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
- Conditions
- Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma
- Trial name
- NCT03635892
- Testing
- cabozantinib, nivolumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, Platinum Resistant Ovarian Cancer
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
- Trial name
- NCT06792552
- Testing
- SIM0505 for injection
- Where
- 17 sites in United States, China
- Volunteers
- 738 people
- Sponsor
- NextCure, Inc.
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other…
- Conditions
- Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT04413123
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bradley A. McGregor, MD
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of…
- Conditions
- Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03541902
- Testing
- Cabozantinib, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Solid Tumor, Advanced Solid Tumor
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic…
- Conditions
- Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT05752552
- Testing
- DO-2
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 55 people
- Sponsor
- DeuterOncology
Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in the body (advanced/metastatic).
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05122546
- Testing
- Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC).
- Conditions
- Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT07243067
- Testing
- Proteomic profiling of urinary EVs, Blood sample collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Mayo Clinic
Kidney Cancer, Renal Cell Carcinoma
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor…
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Clear Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04623502
- Testing
- 13C-Glucose, 13C-Acetate, 13C-Lactate
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Papillary Renal Cell Carcinoma
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not.
- Trial name
- NCT06146777
- Testing
- Pembrolizumab
- Volunteers
- 468 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University